Focus: Roche is a 128-year-old global pharmaceutical giant headquartered in Basel (with operations in Stavanger), employing 100,000 people and specializing in small molecules and diagnostics across oncology, neuroscience, and immunology.
Profile data last refreshed 15h ago · AI intelligence enriched 1mo ago
Hot — 1911 jobs added in 30d
Net +765 (1911 new, 1146 removed). Aggressive expansion phase.
Recent layoff filing — 103 affected
Source: state DOL filings via Big Local News
Roche offers stability and blockbuster drug exposure, but recent mass layoffs and looming patent cliffs require careful evaluation of role durability and long-term career security.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Revenue workhorse representing 23% of company revenue, but approaching loss of exclusivity with no disclosed successor strategy.
Help build intelligence for Roche
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Roche's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Significant oncology franchise in peak commercial phase with 9-year exclusivity runway; flagship ALK inhibitor in non-small cell lung cancer.
Peak-stage biologic with no disclosed LOE date, generating consistent revenue from MS market; less exposed to biosimilar erosion than small molecules.
Orphan-indication biologic in growth phase with 15-year exclusivity; represents Roche's rare-disease oncology expansion.
Small-molecule oncology drug facing patent cliff in December 2028; $103M revenue at risk, triggering likely generic competition within 2 years.
Pioneering monoclonal antibody now facing biosimilar competition and minimal Part D spending; legacy franchise in decline.
Orphan-indication antibody in peak phase; modest revenue reflects rare-disease market size but stable clinical profile.
Checkpoint inhibitor in highly competitive immuno-oncology market; Part D revenue modest despite broad indication portfolio.
Precision-oncology small molecule targeting rare fusion-positive tumors; limited market size reflected in low revenue but high medical significance.
95 discontinued, 26 duplicate formulations not shown
+15 more products with revenue data
Deutsche Bank upgrades Roche stock on oncology survey feedback - Investing.com
Deutsche Bank upgrades Roche stock on oncology survey feedback Investing.com
Roche’s pharma sales grow 7% but pipeline trimmed down - Pharmaceutical Technology
Roche’s pharma sales grow 7% but pipeline trimmed down Pharmaceutical Technology
Roche, In A Buy Zone, Matches Sales Views On Its Diagnostics Beat - Investor's Business Daily
Roche, In A Buy Zone, Matches Sales Views On Its Diagnostics Beat Investor's Business Daily
Roche third-quarter sales rise 7% and beat forecasts, outlook confirmed - The Pharma Letter
Roche third-quarter sales rise 7% and beat forecasts, outlook confirmed The Pharma Letter
Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances - Yahoo Finance
Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances Yahoo Finance
Roche Teases Giredestrant Launch Details in Q3 Earnings Call - GenomeWeb
Roche Teases Giredestrant Launch Details in Q3 Earnings Call GenomeWeb
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+13 more products
+2 more
Source: state DOL filings, aggregated via Big Local News
Recent and ongoing layoffs in a 100,000-person company signal organizational restructuring tied to patent cliff preparation; exercise caution on role permanence, especially in commercial and corporate functions.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo